重症喘息のステロイド抵抗性とその制御

Asthma therapy in general has improved a lot in recent years, but it is still a major problem that severe asthma, which accounts for 10 to 20%, still suffers from strong symptoms on a daily basis despite all therapeutic agents used in combination. American SARP and European ENFUMOSA started in 2000...

Full description

Saved in:
Bibliographic Details
Published in日本薬理学会年会要旨集 p. 2-S27-3
Main Authors 谷本, 安, 山口, 美也子, 大友, 暁美, 大友, 隆之, 中村, 祐人, 濱田, 祐斗, 岩本, 圭右, 永山, 貴紗子, 矢野, 光一, 神山, 智, 森, 晶夫, 岩田, 真紀, 小林, 信之, 関谷, 潔史, 組谷, 千恵美, 上出, 庸介, 渡井, 健太郎, 藤田, 教寛, 松元, 幸一郎, 神沼, 修, 劉, 楷, 福富, 友馬
Format Journal Article
LanguageJapanese
Published 公益社団法人 日本薬理学会 2022
Subjects
Online AccessGet full text
ISSN2435-4953
DOI10.1254/jpssuppl.95.0_2-S27-3

Cover

Abstract Asthma therapy in general has improved a lot in recent years, but it is still a major problem that severe asthma, which accounts for 10 to 20%, still suffers from strong symptoms on a daily basis despite all therapeutic agents used in combination. American SARP and European ENFUMOSA started in 2000 to advance pathophysiological insights of severe asthma. Clinical usage of antibodies and inhibitors against IgE, TNF, IL-5, IL-4, IL-13, and TSLP are also accumulating. Some of these molecular-targeted drugs improve respiratory function and reduce acute exacerbations in patients with severe asthma. Until now, cytokines have been assumed to be involved in chronic inflammation, but it is also interesting to elucidate the pathways of how cytokines are involved in respiratory function and acute exacerbations. We registered approximately 100 steroid-dependent asthma patients in Japan. Although long-lasting poor control of the disease was considered the cause of severe asthma in the past, steroid dependence in one third of the cases occurred within 2-3 years after the onset. Steroid resistance seems a key process from the early stage of the disease. Steroid resistance of T cell level was induced by extracellular co-stimulation and cytokine signals. The inhibition may improve steroid sensitivity and treat steroid-resistant asthma. Therefore, we established a steroid-resistant asthma model for the first time by transferring steroid resistant T cell clones, and analyzed the steroid sensitivity recovery effect of CTLA4-Ig. In addition, a multicenter, double-blind, placebo-controlled exploratory trial was performed as a POC study investigating the efficacy of abatacept in treatment-resistant severe asthma. Elucidation of the pathophysiology and mechanism by which steroids do not work is expected to be a breakthrough for the prevention and treatment of severe asthma.
AbstractList Asthma therapy in general has improved a lot in recent years, but it is still a major problem that severe asthma, which accounts for 10 to 20%, still suffers from strong symptoms on a daily basis despite all therapeutic agents used in combination. American SARP and European ENFUMOSA started in 2000 to advance pathophysiological insights of severe asthma. Clinical usage of antibodies and inhibitors against IgE, TNF, IL-5, IL-4, IL-13, and TSLP are also accumulating. Some of these molecular-targeted drugs improve respiratory function and reduce acute exacerbations in patients with severe asthma. Until now, cytokines have been assumed to be involved in chronic inflammation, but it is also interesting to elucidate the pathways of how cytokines are involved in respiratory function and acute exacerbations. We registered approximately 100 steroid-dependent asthma patients in Japan. Although long-lasting poor control of the disease was considered the cause of severe asthma in the past, steroid dependence in one third of the cases occurred within 2-3 years after the onset. Steroid resistance seems a key process from the early stage of the disease. Steroid resistance of T cell level was induced by extracellular co-stimulation and cytokine signals. The inhibition may improve steroid sensitivity and treat steroid-resistant asthma. Therefore, we established a steroid-resistant asthma model for the first time by transferring steroid resistant T cell clones, and analyzed the steroid sensitivity recovery effect of CTLA4-Ig. In addition, a multicenter, double-blind, placebo-controlled exploratory trial was performed as a POC study investigating the efficacy of abatacept in treatment-resistant severe asthma. Elucidation of the pathophysiology and mechanism by which steroids do not work is expected to be a breakthrough for the prevention and treatment of severe asthma.
Author 岩本, 圭右
永山, 貴紗子
松元, 幸一郎
濱田, 祐斗
谷本, 安
矢野, 光一
神沼, 修
大友, 暁美
関谷, 潔史
福富, 友馬
森, 晶夫
組谷, 千恵美
小林, 信之
大友, 隆之
上出, 庸介
渡井, 健太郎
中村, 祐人
神山, 智
藤田, 教寛
岩田, 真紀
山口, 美也子
劉, 楷
Author_xml – sequence: 1
  fullname: 谷本, 安
  organization: 国立病院機構南岡山医療センター
– sequence: 1
  fullname: 山口, 美也子
  organization: 国立病院機構相模原病院・臨床研究センター・先端技術開発研究部
– sequence: 1
  fullname: 大友, 暁美
  organization: 国立病院機構相模原病院・臨床研究センター・先端技術開発研究部
– sequence: 1
  fullname: 大友, 隆之
  organization: 東京薬科大・薬・臨床医療薬学センター
– sequence: 1
  fullname: 中村, 祐人
  organization: 国立病院機構相模原病院・アレルギー呼吸器科
– sequence: 1
  fullname: 濱田, 祐斗
  organization: 国立病院機構相模原病院・アレルギー呼吸器科
– sequence: 1
  fullname: 岩本, 圭右
  organization: 国立病院機構相模原病院・アレルギー呼吸器科
– sequence: 1
  fullname: 永山, 貴紗子
  organization: 国立病院機構相模原病院・アレルギー呼吸器科
– sequence: 1
  fullname: 矢野, 光一
  organization: 国立病院機構相模原病院・アレルギー呼吸器科
– sequence: 1
  fullname: 神山, 智
  organization: 国立病院機構相模原病院・臨床研究センター・先端技術開発研究部
– sequence: 1
  fullname: 森, 晶夫
  organization: 国立病院機構相模原病院・臨床研究センター・先端技術開発研究部
– sequence: 1
  fullname: 岩田, 真紀
  organization: 国立病院機構相模原病院・アレルギー呼吸器科
– sequence: 1
  fullname: 小林, 信之
  organization: 国立病院機構東京病院
– sequence: 1
  fullname: 関谷, 潔史
  organization: 国立病院機構相模原病院・アレルギー呼吸器科
– sequence: 1
  fullname: 組谷, 千恵美
  organization: 国立病院機構相模原病院・臨床研究センター・先端技術開発研究部
– sequence: 1
  fullname: 上出, 庸介
  organization: 国立病院機構相模原病院・アレルギー呼吸器科
– sequence: 1
  fullname: 渡井, 健太郎
  organization: 国立病院機構相模原病院・アレルギー呼吸器科
– sequence: 1
  fullname: 藤田, 教寛
  organization: 国立病院機構相模原病院・アレルギー呼吸器科
– sequence: 1
  fullname: 松元, 幸一郎
  organization: 九州大・医・胸部疾患研究所
– sequence: 1
  fullname: 神沼, 修
  organization: 広島大・原爆放射線医科学研究所・疾患モデル解析研究分野
– sequence: 1
  fullname: 劉, 楷
  organization: 国立病院機構相模原病院・アレルギー呼吸器科
– sequence: 1
  fullname: 福富, 友馬
  organization: 国立病院機構相模原病院・アレルギー呼吸器科
BookMark eNo9j8tKw0AARQdRsNZ-gp-QOM8ks5RiVSi4UNfDzGSiCbGGpC7cmRasFtxaNy4EQTfqSsGNPzMk4l8Y8bG5lwuHC2cJzA-OBgaAFQRdhBldTbKiOM6y1OXMhQI7O9h3yBxoYUqYQzkji6BTFLGClPqMMsRbwPucXH7MJtXVdV0-2_LJjt7s-MyOH-3ozo4v6ulLPZ3Vp_e2fLDlTQNU56_V--0yWIhkWpjOb7fBXm99t7vp9Lc3trprfSdBHoaOhFIrQrGJuBeEyOcaSU1DGjCqAhOqkDOuODEk0ko3i0tIpEcggh4zNFKkDXo_v0kxlPtGZHl8KPMTIfNhrFMj_owFZwJ-BxaNtCD_gD6QuUgk-QIxy2rR
ContentType Journal Article
Copyright 2022 本論文著者
Copyright_xml – notice: 2022 本論文著者
DOI 10.1254/jpssuppl.95.0_2-S27-3
DatabaseTitleList
DeliveryMethod fulltext_linktorsrc
EISSN 2435-4953
ExternalDocumentID article_jpssuppl_95_0_95_2_S27_3_article_char_ja
GroupedDBID ALMA_UNASSIGNED_HOLDINGS
JSF
RJT
ID FETCH-LOGICAL-j1620-a0acb342ef968d179c1ac4d4854b8edbd959b93e3fcbcbd99a03a6301065e4fb3
IngestDate Wed Sep 03 06:30:46 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed false
IsScholarly false
Language Japanese
LinkModel OpenURL
MeetingName 日本薬理学会年会要旨集 第95回日本薬理学会年会
MergedId FETCHMERGED-LOGICAL-j1620-a0acb342ef968d179c1ac4d4854b8edbd959b93e3fcbcbd99a03a6301065e4fb3
Notes 95_2-S27-3
OpenAccessLink https://www.jstage.jst.go.jp/article/jpssuppl/95/0/95_2-S27-3/_article/-char/ja
ParticipantIDs jstage_primary_article_jpssuppl_95_0_95_2_S27_3_article_char_ja
PublicationCentury 2000
PublicationDate 2022
PublicationDateYYYYMMDD 2022-01-01
PublicationDate_xml – year: 2022
  text: 2022
PublicationDecade 2020
PublicationTitle 日本薬理学会年会要旨集
PublicationYear 2022
Publisher 公益社団法人 日本薬理学会
Publisher_xml – name: 公益社団法人 日本薬理学会
SSID ssib044754519
ssj0003321863
ssib041654217
Score 1.8601602
Snippet Asthma therapy in general has improved a lot in recent years, but it is still a major problem that severe asthma, which accounts for 10 to 20%, still suffers...
SourceID jstage
SourceType Publisher
StartPage 2-S27-3
SubjectTerms allergy
Title 重症喘息のステロイド抵抗性とその制御
URI https://www.jstage.jst.go.jp/article/jpssuppl/95/0/95_2-S27-3/_article/-char/ja
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
ispartofPNX 日本薬理学会年会要旨集, 2022, pp.2-S27-3
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3Na9RAFA-1XryIouI3PTgnSc1mMl8nmdlmKUK92EJvIZNkD3uoRbYXD-K2YLXg1XrxIAh6UU8KHvSfCV3xv_C9yaQbpKCtEIa3kze_-e287L73hplJENwacmETCBVC3KYICUrOQmWZCEsqhKh4AUExTg2s3OfLa8m9dbY-d-p7Z9XS1tguFo-P3FdyEqtCHdgVd8kew7KHoFABMtgXSrAwlP9kY5IqAsm8XCKpIEqgnDKiOFGSpByCRKIHJKVOSJ0QE6OcABf3gl7yt3TS3lKuuSaGeQHAUYiIFi2g9IJa6nTBiJTEcBRMSnSvG_siAuBoh6n6RPdJKpEtCsA_cpQY8tEgJMT0idIOShGTdGokKkCPHlDiOChD5OEsI6qYiBgx6woeJQeeEqlmaoDdwwuJD4imjZpA8jJ1PQLywLNSUbchjJYWvqE0TUOO9JCYR_ibvnL63HckTXcOJp7l6q4Va8fJoEFAAEDjhhxqgDl0bihRzIGB6fTtkw1447Kdb4ghyg1xaXDX94QPYnAYR_rFmCXoFzfhtwzJzaJii1HW0f_jyHH_QGetfqZYFmERZ9Ako1mrgDsDsxGkJ6djIXq4onblSdr-nSe4US6eZc94tCQeZnQ4BUopvhCN-n11QPHOkQQhNhxBptSusnSB3-q54KzP2BZ0Q-Z8MDfKLwT81-7Ln_u7B69eTyef68mnevtbvfOs3vlYb7-rd15M975M9_anT9_Xkw_15A0oHDz_evDj7cVgbZCu9pdD_wqScNTjcRTmUV5YmsTVUHFZgvMqenmRlIlkiZVVaUvFlFW0osPCFvBJ5RHNOcWJFlYlQ0svBfMbDzeqy8GCyjkkU8zGAqLm3DI5ZJEtaTmkUVxWIr8S3G2-ZrbZnDOTHdcMV_8b4VpwBh_vZorxejA_frRV3YCge2xvOtP-BpboqAU
linkProvider ISSN International Centre
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=%E9%87%8D%E7%97%87%E5%96%98%E6%81%AF%E3%81%AE%E3%82%B9%E3%83%86%E3%83%AD%E3%82%A4%E3%83%89%E6%8A%B5%E6%8A%97%E6%80%A7%E3%81%A8%E3%81%9D%E3%81%AE%E5%88%B6%E5%BE%A1&rft.jtitle=%E6%97%A5%E6%9C%AC%E8%96%AC%E7%90%86%E5%AD%A6%E4%BC%9A%E5%B9%B4%E4%BC%9A%E8%A6%81%E6%97%A8%E9%9B%86&rft.au=%E8%B0%B7%E6%9C%AC%2C+%E5%AE%89&rft.au=%E5%B1%B1%E5%8F%A3%2C+%E7%BE%8E%E4%B9%9F%E5%AD%90&rft.au=%E5%A4%A7%E5%8F%8B%2C+%E6%9A%81%E7%BE%8E&rft.au=%E5%A4%A7%E5%8F%8B%2C+%E9%9A%86%E4%B9%8B&rft.date=2022&rft.pub=%E5%85%AC%E7%9B%8A%E7%A4%BE%E5%9B%A3%E6%B3%95%E4%BA%BA+%E6%97%A5%E6%9C%AC%E8%96%AC%E7%90%86%E5%AD%A6%E4%BC%9A&rft.eissn=2435-4953&rft.spage=2-S27-3&rft_id=info:doi/10.1254%2Fjpssuppl.95.0_2-S27-3&rft.externalDocID=article_jpssuppl_95_0_95_2_S27_3_article_char_ja